ERRB2 (formerly HER2)-positive advanced breast cancer (ABC) remains typically incurable with optimal treatment undefined in later lines of therapy. The chimeric antibody margetuximab shares ERBB2 specificity with trastuzumab but incorporates an engineered Fc region to increase immune activation.
Rugo, H.S., Im, S., Cardoso, F., Cortés, J., Curigliano, G., Musolino, A., et al. (2021). Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA ONCOLOGY, 7(4), 573-584 [10.1001/jamaoncol.2020.7932].
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial
Musolino, Antonino;
2021
Abstract
ERRB2 (formerly HER2)-positive advanced breast cancer (ABC) remains typically incurable with optimal treatment undefined in later lines of therapy. The chimeric antibody margetuximab shares ERBB2 specificity with trastuzumab but incorporates an engineered Fc region to increase immune activation.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
jamaoncology_rugo_2021_oi_200114_1611083625.00813 (1).pdf
accesso aperto
Tipo:
Versione (PDF) editoriale / Version Of Record
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione
453.38 kB
Formato
Adobe PDF
|
453.38 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
